NIH Cleared of Tampering with Ethics Probe

Government auditors absolve the National Institutes of Health of wrongdoing in the case of its involvement in an ethics investigation of a study involving premature babies.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, USAIDThe National Institutes of Health (NIH) did not act improperly last year when it persuaded an independent investigatory panel to walk back its threats to censure researchers who had conducted a study that subjected preterm infants to dangerously low levels of oxygen, according to the Office of the Inspector General at the US Department of Health and Human Services (HHS). The HHS inspector general issued two reports this week detailing the events that occurred last spring when questions were raised about how the NIH inserted itself into an ethics probe of researchers who conducted a trial of oxygen regimes involving more than 1,300 extremely premature infants from 2005 to 2009.

The government’s Office of Human Research Protections (OHRP) was investigating researchers at the University of Alabama, Birmingham (UAB), where the so-called SUPPORT trial was centered, expressing concern that informed consent forms provided to parents enrolling their children in the study did not adequately warn them of the potential dangers of the experimental O2 treatments. In a letter written to UAB officials, the OHRP threatened that some of the researchers running the trial would have to be penalized for their lapses. But three months later, the OHRP changed its tune, suspending its call to sanction the scientists.

Federal watchdog group Public Citizen cried foul, alleging that NIH officials improperly influenced the OHRP investigators. The reports released this week concluded that neither the NIH nor OHRP acted ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies